Pfizer to License RAGE Modulators from TransTech

Published on: 

Pfizer (New York, NY, www.pharmtech.com) will license TransTech Pharma's (High Point, NC, www.ttpharma.com) portfolio of large- and small-molecule compounds that target the receptor for advanced glycation end products (RAGE), which have potential use in treating Alzheimer's disease.

Pfizer (New York, NY, www.pfizer.com) will license TransTech Pharma’s (High Point, NC, www.ttpharma.com) portfolio of large- and small-molecule compounds that target the receptor for advanced glycation end products (RAGE), which have potential use in treating Alzheimer’s disease. The most advanced molecules include TTP4000, a large-molecule compound expected to enter Phase 1 trials this year, and TTP488, a small-molecule compound that has completed a Phase 2a study.